Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.34 |
| ▸ | MITF | O75030 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.31 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.31 |
| ▸ | PREP | P48147 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10187689 | 0.71 | HPGD (0.38) | HPGDSMN1; SMN2POLBMAPK1LMNA | |
| SCHEMBL22016195 | 0.70 | SMN1; SMN2 (0.32) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL29161623 | 0.68 | ALDH1A1 (0.40) | HPGDSMN1; SMN2POLBMAPK1LMNA | |
| SCHEMBL21727169 | 0.68 | HTR2C (0.41) | HPGDMAPK1 | |
| SCHEMBL10183602 | 0.67 | MAPK1 (0.50) | HPGDSMN1; SMN2POLBMAPK1LMNA | |
| SCHEMBL12857326 | 0.67 | SSTR4 (0.49) | HPGDSMN1; SMN2POLBMAPK1LMNA | |
| SCHEMBL13057511 | 0.67 | NPC1 (0.33) | HPGDSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL14396591 | 0.67 | HPGD (0.33) | HPGDLMNAHTTAPOBEC3AAPOBEC3G | |
| SCHEMBL29161593 | 0.65 | ALDH1A1 (0.38) | HPGDSMN1; SMN2POLBMAPK1GAA | |
| SCHEMBL20434829 | 0.64 | SSTR4 (0.50) | HPGDSMN1; SMN2POLBMAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340505-B2 | Type III secretion inhibitors, analogs and uses thereof | UNIVERSITY OF MASSACHUSETTS (US) | 2016-05-17 | — | — | US | disclosed |
| US-20140323483-A1 | TYPE III SECRETION INHIBITORS, ANALOGS AND USES THEREOF | UNIVERSITY OF MASSACHUSETTS (US) | 2014-10-30 | — | — | US | disclosed |
| US-20110034463-A1 | TYPE III SECRETION INHIBITORS, ANALOGS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034463-A1 | TYPE III SECRETION INHIBITORS, ANALOGS AND USES THEREOF | GBA3, CLPP, PEX3 | HPGD 2825/4885MITF 2608/4885SMN1; SMN2 4655/4885 |
| US-20140323483-A1 | TYPE III SECRETION INHIBITORS, ANALOGS AND USES THEREOF | GBA3, CLPP, PEX3 | HPGD 2825/4885MITF 2608/4885SMN1; SMN2 4655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.